Rather, we recommend the use of the CRP/albumin ratio in conjunction with other prognostic scoring systems or laboratory parameters to predict the short-term prognosis of patients with STEMI, as it is an inexpensive, reproducible, systemic biomarker of inflammation and therefore of CAD. This evidence concerns the gene CRP and coronary artery disorder.